英国新冠疫情期间主动疫苗安全监测的实施与结果:监管视角
英国药品和健康产品管理局(MHRA)建立黄卡疫苗监测平台(YCVM),对新冠疫苗接种后疑似不良反应进行主动监测。孕妇和哺乳期女性未发现安全信号,月经紊乱报告受媒体关注刺激,耳鸣数据支持监管行动。
要点
- YCVM主动监测补充了新冠疫苗安全性监测数据源。
- 52.1%报告接种者经历至少一种不良反应,多为预期急性反应。
- 孕妇和哺乳期女性数据未提出安全担忧。
核心结论
- YCVM主动监测为新冠疫苗安全性监测提供了补充数据源。
- 需进一步努力招募少数族裔人群。
- 开发的技术增强了监管警戒选项,未来可用于小人群创新产品主动监测。
研究设计与样本
- 基于英国MHRA建立的黄卡疫苗监测平台(YCVM),采用分层随机抽样邀请个体注册并主动联系获取疫苗和不良反应信息。
- 登记36604人,其中30281人报告接种,中位随访184天(IQR 14-367)。
- 对孕妇和哺乳期女性亚队列进行详细分析,并提取月经紊乱和耳鸣数据展示对监管评估的支持。
主要发现
- 15764人(52.1%)报告至少一种不良反应,几乎均为预期急性反应。
- 4134人(13.7%)报告医学严重事件。
- 孕妇和哺乳期女性数据未提出安全担忧。
- 月经紊乱报告似乎受媒体兴趣刺激,与自发报告系统所见相似。
- 耳鸣发生率数据用于支持对该信号的监管行动。
临床怎么用
- 主动监测平台可作为传统自发报告系统的补充,用于疫苗安全性信号检测与评估。
- 对孕妇、哺乳期女性等临床试验中代表性不足人群可开展亚队列主动监测。
局限性
- 需进一步努力招募少数族裔人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Yellow Card Vaccine Monitor (YCVM) was established by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to facilitate active monitoring of adverse drug reactions following COVID-19 vaccination and further characterise safety in populations under-represented in clinical trials. OBJECTIVE: This study explored the profile of individuals registered to the YCVM platform and the suspected adverse drug reactions reported following a COVID-19 vaccination on this data platform. METHODS: Using a stratified random selection approach, individuals were invited to register and actively contacted to seek further information on the vaccines received and adverse reactions they experienced. Exploratory analyses were conducted to characterise the demographics of individuals registered in the YCVM, and to summarise the adverse drug reaction data reported by recruited individuals between November 2020 and December 2022. Detailed analyses of the sub-cohort of pregnant and breastfeeding females were conducted to characterise these individuals. Data for two suspected adverse reactions, menstrual disorders and tinnitus, were extracted and analysed to demonstrate how YCVM supported regulatory assessment of these safety signals which originally arose from other data sources. RESULTS: 36,604 individuals registered, with 30,281 reporting vaccination. Median (interquartile range) follow-up was 184 days (14-367). Demographics of the recruited cohort reflected the vaccinated population and timing of invitations. 15,764 (52.1%) of those reporting vaccination reported experiencing at least one adverse reaction. However, nearly all were expected acute reactions and 4134 (13.7%) reported an event considered medically serious. The data raised no safety concerns in pregnant and breastfeeding females. Reporting of menstrual disorders appeared stimulated by media interest, as seen in spontaneous reporting systems. Data on the incidence of tinnitus were used to support regulatory action on this signal. CONCLUSION: Active surveillance using the YCVM provided a complementary data source for monitoring the safety of COVID-19 vaccines. However, further efforts are needed to recruit ethnic minorities. The technology developed has enhanced regulatory vigilance options and could be valuable in the future for actively monitoring the safety of innovative products used in small populations.
引用
- Wong J, Donegan K, Harrison K, et al. Implementation and Results of Active Vaccine Safety Monitoring During the COVID-19 Pandemic in the UK: A Regulatory Perspective. Drug Saf. 2025. PMID: 40900408. doi:10.1007/s40264-025-01579-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。